Learning About New HIV Prevention for Young Women
This study helps researchers understand how to share accurate information about lenacapavir, a newer HIV prevention method, with young women in South Africa. You'll participate in educational activities and share your thoughts to help improve how this information reaches people who need it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You identify as female (cisgender or transgender)
- You are between 18 and 29 years old
- You've been sexually active in the past 12 months
- You are HIV-negative or unsure of your HIV status
- You can read and understand English
- You are willing and able to consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with HIV who are starting or have recently started a treatment using two long-acting medications, cabotegravir and lenacapavir. It aims to see how well this combination works in real life, which could help improve care for others.
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
This study tests a new injectable medication called lenacapavir to prevent HIV infection. You get to choose between different HIV prevention options, and the study will see how well the injection works for you.
This study tests if giving a long-acting HIV prevention shot (lenacapavir) from a mobile medical van can reach people at risk for HIV in Los Angeles County. You may be able to join if you are HIV negative, at risk for HIV, and are willing to try a shot instead of a daily pill.
This trial tests a new HIV prevention medicine called lenacapavir, given as a shot every six months. It's for young people at risk of HIV who haven't used PrEP before or have had gaps in their PrEP use.
This study offers a long-acting injectable form of PrEP (lenacapavir) to prevent HIV in Latine transgender women and gay men in the South. It aims to make HIV prevention easier by providing a shot instead of a daily pill.
Hear when a new Misinformation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.